Marc Goodman
Stock Analyst at Leerink Partners
(3.63)
# 1,283
Out of 5,180 analysts
95
Total ratings
57.14%
Success rate
21.51%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGP SpyGlass Pharma | Initiates: Outperform | $42 | $24.44 | +71.85% | 1 | Mar 3, 2026 | |
| MANE Veradermics | Initiates: Outperform | $75 | $58.78 | +27.59% | 1 | Mar 2, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $150 → $205 | $171.78 | +19.34% | 8 | Jan 28, 2026 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $8 | $2.09 | +282.78% | 1 | Jan 12, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $20.83 | +44.02% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $2.16 | +131.48% | 1 | Nov 17, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $24.81 | +37.04% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $9.62 | +419.75% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $14.35 | -30.31% | 5 | May 7, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $7.10 | -85.92% | 3 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $9.35 | +242.25% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $167.25 | -85.05% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $19.68 | +154.07% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $4.31 | +364.04% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $132.56 | -13.25% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $183.78 | +68.68% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $56.69 | -18.86% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $22.32 | -5.91% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $188.27 | +11.54% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.79 | +258.42% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $35.05 | -22.97% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $1.68 | +792.86% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $536.61 | -49.68% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $214.98 | -55.34% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $61.73 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $120.84 | -44.55% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $11.00 | +790.91% | 7 | Oct 5, 2017 |
SpyGlass Pharma
Mar 3, 2026
Initiates: Outperform
Price Target: $42
Current: $24.44
Upside: +71.85%
Veradermics
Mar 2, 2026
Initiates: Outperform
Price Target: $75
Current: $58.78
Upside: +27.59%
Axsome Therapeutics
Jan 28, 2026
Maintains: Outperform
Price Target: $150 → $205
Current: $171.78
Upside: +19.34%
Neumora Therapeutics
Jan 12, 2026
Initiates: Outperform
Price Target: $8
Current: $2.09
Upside: +282.78%
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $20.83
Upside: +44.02%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $2.16
Upside: +131.48%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $24.81
Upside: +37.04%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $9.62
Upside: +419.75%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $14.35
Upside: -30.31%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $7.10
Upside: -85.92%
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $9.35
Upside: +242.25%
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $167.25
Upside: -85.05%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $19.68
Upside: +154.07%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $4.31
Upside: +364.04%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $132.56
Upside: -13.25%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $183.78
Upside: +68.68%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $56.69
Upside: -18.86%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $22.32
Upside: -5.91%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $188.27
Upside: +11.54%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.79
Upside: +258.42%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $35.05
Upside: -22.97%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $1.68
Upside: +792.86%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $536.61
Upside: -49.68%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $214.98
Upside: -55.34%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $61.73
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $120.84
Upside: -44.55%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $11.00
Upside: +790.91%